



KDIGO Form* for Disclosure of Potential Competing Interests

1. INSTRUCTIONS

This form will provide the public with information about your other interests that could influence how they perceive your work for KDIGO. All KDIGO volunteers should submit a form and vouch for its accuracy. This is part of the KDIGO commitment to total transparency in all its activities.

2. IDENTIFYING INFORMATION

1. Given Name (First Name): Sydney
 2. Surname (Last Name): Tang
 3. Date: 9 Feb 2023
 4. Title and Organization/Affiliation: Professor, The University of Hong Kong
-

3. RELEVANT ACTIVITIES

This section asks about your financial relationships with industry, non-government, and government bodies and non-financial interests that may give the appearance of potentially influencing your work with KDIGO. You should disclose interactions with any entity that might be considered broadly related to the work being conducted for KDIGO or for the topic under consideration (e.g., the topic of the guideline for which you will be a Work Group member).

Report all sources of revenue paid (or promised to be paid) directly to you or to your institution on your behalf over the last 24 months.

Regarding non-financial interests, it is expected that you will have previous activities that are conceptually linked to your work with KDIGO.

Place an “x” in the appropriate boxes to indicate whether you have financial relationships with entities (>€500) or non-financial interests as described in the instructions. You should report relationships that were present during the last 24 months or that you expect within the next 12 months. Complete each question by selecting “None” or providing the requested information.

For examples of the various types of interest, please see [Appendix A. Examples of competing interests and management](#). All questions refer to your work with KDIGO or the topic under consideration related to your work with KDIGO.

Financial disclosures of interest						
		Name all entities with whom you have this relationship or indicate none (add rows as needed)				Comments
1	Support for any study or manuscript pertaining to the topic of interest (e.g., funding, provision of study materials, medical writing, article processing charges)	<input checked="" type="checkbox"/> None				
		Entity	Paid to you	Paid to institution	Relevant to topic of interest	Not relevant to topic of interest
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2	Grants or contracts from any entity (if not indicated in item #1 above) related to the topic of interest	<input checked="" type="checkbox"/> None				
		Entity	Paid to you	Paid to institution	Relevant to topic of interest	Not relevant to topic of interest
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3	Royalties or licenses	<input checked="" type="checkbox"/> None				
		Entity	Paid to you	Paid to institution	Relevant to topic of interest	Not relevant to topic of interest
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4	Consulting fees	<input type="checkbox"/> None				
		Entity	Paid to you	Paid to institution	Relevant to topic of interest	Not relevant to topic of interest
		Eledon Pharmaceuticals	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
5	Payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events	<input type="checkbox"/> None				
		Entity	Paid to you	Paid to institution	Relevant to topic of interest	Not relevant to topic of interest
		Bayer AG	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
		AstraZeneca	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
		Novartis	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
6	Payment for expert testimony	<input checked="" type="checkbox"/> None				
		Entity	Paid to you	Paid to institution	Relevant to topic of interest	Not relevant to topic of interest
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7	Funding for travel and/or accommodation	<input checked="" type="checkbox"/> None				
		Entity	Paid to you	Paid to institution	Relevant to topic of interest	Not relevant to topic of interest
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8	Patents planned, issued, or pending	<input checked="" type="checkbox"/> None				
		Entity	Paid to you	Paid to institution	Relevant to topic of interest	Not relevant to topic of interest
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None				
		Entity	Paid to you	Paid to institution	Relevant to topic of interest	Not relevant to topic of interest
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10	Any <i>paid</i> leadership or fiduciary role in other board,	<input checked="" type="checkbox"/> None				
		Entity		Paid to you	Paid to institution	

	society, committee, or advocacy group relevant to the topic of interest		<input type="checkbox"/>	<input type="checkbox"/>		
			<input type="checkbox"/>	<input type="checkbox"/>		
			<input type="checkbox"/>	<input type="checkbox"/>		
11	Stock or stock options	<input checked="" type="checkbox"/> None				
		Entity	Paid to you	Paid to institution	Relevant to topic of interest	Not relevant to topic of interest
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
12	Receipt of equipment, materials, drugs, medical writing, gifts, or other services	<input checked="" type="checkbox"/> None				
		Entity	Paid to you	Paid to institution	Relevant to topic of interest	Not relevant to topic of interest
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
13	Other <i>financial</i> interests relevant to the topic of interest	<input checked="" type="checkbox"/> None				
		Entity	Paid to you	Paid to institution		
			<input type="checkbox"/>	<input type="checkbox"/>		
			<input type="checkbox"/>	<input type="checkbox"/>		
			<input type="checkbox"/>	<input type="checkbox"/>		
Non-financial disclosures of interest						
		<p>Other relationships, activities, or publications that a reasonable person might perceive as potentially influencing your work with KDIGO. Unsupported research publications on a given drug or condition, membership of governmental, non-governmental, advocacy, or lobbying organization, and serving as an expert witness are all examples of non-financial interests that should be disclosed; other examples exist. Please see Appendix A.</p> <p>Examples of competing interests and management for more details.</p>				
1	Any <i>unpaid</i> leadership or fiduciary role in other board, society, committee, or advocacy group relevant to the topic of interest	<input type="checkbox"/> None				
		Entity	Paid to you	Paid to institution		
		Asian Pacific Society of Nephrology	<input type="checkbox"/>	<input type="checkbox"/>		
		International Society of Nephrology	<input type="checkbox"/>	<input type="checkbox"/>		
			<input type="checkbox"/>	<input type="checkbox"/>		

2	Other <i>non-financial</i> interests relevant to the topic of interest	<input type="checkbox"/> None <input type="checkbox"/> Yes If yes, please describe	
----------	---	--	--

Appendix A. Examples of competing interests and management

Example 1: Personal financial, Specific:

Consultancy fee received by a Work Group member from the company producing a product in the class of therapies under consideration, or a product in the comparator class

Action required: Depends on the nature of the consultancy undertaken and the details of the guideline. In general, KDIGO does not recommend specific products in their guideline statements, but rather provides class-based statements.

- Complete exclusion – if the interest relates specifically to a product under consideration, or its comparator. The interest is a specific, personal, financial interest.
- Declare and remain – if the consultancy is unrelated to a specific product under consideration for the guideline or its comparator. The interest is not specific.

If the consultancy income from the manufacturer of a specific product under review (or a relevant comparator) accounts for a large proportion of the person's income then it would be appropriate to exclude the person from the decision-making.

Example 2: Personal non-financial, Specific

A member of the Work Group for the guideline on condition A has published several papers supporting the use of drug X as first line management of condition A, including a randomized trial and two review articles. The WG is now discussing treatment options for condition A.

Action required: Potential exclusion – this is non-financial, personal, and professional interest and the response will depend on the nature of the view expressed and the risk to perceived objectivity. In determining the level of involvement, the Guideline Chair(s) should consider the balance between this risk and the benefit of the member's input to the Guideline Work Group. In this example, the WG member might derive considerable professional benefit if drug A were recommended as the first-choice treatment in KDIGO guidance on condition A. Therefore, this interest may compromise the member's objectivity (or perceived objectivity) and exclusion may be most appropriate. Open declaration or partial exclusion (i.e., the member to remain in the room to answer questions but not take part in decision-making) will often be sufficient.

In contrast, a WG member who wrote a review article on condition X might not necessarily have a relevant non-financial interest, unless the article took an unusually strong position on drug A or an alternative

Example 3: Non-personal financial, Specific

Grant income received by the Work Group member's employer from the company that manufactures the product.

Action required: Declare and remain – this is a non-personal, financial interest. Because the income goes to the employer, there is no strong conceptual link between this publication and potential benefit to the WG member, regardless of what the guideline recommends. Therefore, there is no realistic threat to objectivity.

Example 4: Personal financial, Non-specific:

Consultancy fees received by a Work Group member from a company with a product unrelated to the guideline

Action required: Declare and remain – there is no strong conceptual link between this publication and potential benefit to the WG member, regardless of what the guideline recommends. Therefore, there is no realistic threat to objectivity.

Example 5: Personal non-financial, Non-specific

Research publications covering epidemiology of condition X, for a WG member on a guideline panel for condition X, where condition X is a complication of CKD.

Action required: Declare above and remain –there is no strong conceptual link between this publication and potential benefit to the WG member, regardless of what the guideline recommends. Therefore, there is no realistic threat to objectivity. If the publications were further removed from the guideline topic (e.g., the member had published extensively on the epidemiology of CKD, but not on condition X specifically) then disclosure would not be required.

Example 6: Non-personal financial, Non-specific

The member's institution or organization receives government funding for evidence reviews not related to the guideline topic.

Action required: These interests typically do not require disclosure except under exceptional circumstances. Again, the test is whether the interest could be perceived as compromising the integrity of the guideline. For example, if a government had a strongly stated policy position that was relevant to a guideline, and if contravening that position could conceivably lead to withdrawal of funding from the member's institution, then in theory this interest might require disclosure and management. In practice, such circumstances are unlikely to occur.